This is the authors' abstract. We don't add key points for this paper.
Objective: To study the effect of HPLC purified herbal anti-hyperglycemic active compound (FIIc) isolated from the fruit pulp of Eugenia jambolana in diabetic rats.Methods: 24 male wistar rats were taken and diabetes was induced in group B, C and D rats (n = 6 each) by injecting Streptozotocin at a dose of 45 mg/kg of body weight 15 minutes after Nicotinamide at a dose 230 mg/kg body weight intraperitoneally after overnight fasting. Active compound (FIIc) was given to group C and Pioglitazone to group D at dose of 20 mg/kg of body weight orally for 4 weeks respectively. Glycemic and lipid profile, protein tyrosine kinase activity and serum DPP-4 levels were measured and compared between all the 4 study groups.Results: Significant Improvement in body weight, glycemic profile, dyslipidemia and tyrosine kinase activity (4.90 ± 1.28 U/mg protein) were observed in FIIc treated rats at week 4 of the study compared to diabetic control rats. Serum DPP-4 levels (26.41 ± 0.43 pg/ml) were also found to be decreased in FIIc treated rats at week 4 of the study compared to diabetic control rats. This is possibly due to increased serum insulin levels and increased insulin sensitivity after treatment with active compound FIIc.Conclusion: FIIc significantly reduced hyperglycemia and dyslipidemia by inhibiting DPP-4 levels and improves insulin sensitivity by increasing protein tyrosine kinase activity and serum insulin levels.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Suman Sharma (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: